• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Eli Lilly (LLY) Posts Drug Trial Wins As Pipeline Progress Meets Legal Setbacks

    Simply Wall St·10/03/2026 03:19:56
    Listen to the news
    • Eli Lilly (NYSE:LLY) reported new clinical data on obesity drug Foundayo, diabetes candidate EloraTZP, and dermatitis therapy EBGLYSS, alongside plans for regulatory filings.
    • The firm ended its cancer-drug collaboration with Foghorn Therapeutics, which Foghorn said is driving sizeable workforce reductions.
    • A recent jury verdict found Lilly breached a collaboration agreement with Nektar Therapeutics, with damages awarded to Nektar.
    • These fresh Foundayo, EloraTZP, and EBGLYSS milestones, plus the Nektar verdict, sit within a broader picture our research has uncovered. We have also spotted 1 warning sign worth knowing about at Eli Lilly.

    For more context on where Lilly fits in the broader healthcare story, explore other stocks in this sector through 35 healthcare AI stocks.

    NYSE:LLY Earnings & Revenue Growth as at Oct 2026
    NYSE:LLY Earnings & Revenue Growth as at Oct 2026

    Eli Lilly is a US pharmaceutical group that discovers and manufactures treatments across major disease areas, so new weight loss, diabetes and dermatitis programs feed directly into its core pipeline. Partnership shifts and legal disputes highlight how dependent this model is on external collaborators as well as in-house research.

    3 things going right for Eli Lilly that this headline doesn't cover.

    What it means for investors

    The latest data keeps Eli Lilly’s Narrative firmly centered on cardiometabolic medicines as the main engine, while also surfacing execution and governance risks. Foundayo, EloraTZP and EBGLYSS all feed the existing bull case that Lilly can extend its GLP‑1 and dermatology franchises through more indications and convenient oral or combination options. That aligns with the view that a concentrated portfolio in obesity and diabetes can still support long term earnings, provided manufacturing and access keep pace with demand.

    See how these catalysts shape Eli Lilly's path to a $1,325 fair value.

    The bear-side concerns also get fresh evidence. Ending the Foghorn cancer collaboration and the jury finding against Lilly in the Nektar case reinforce the Narrative risk around reliance on partnerships and legal exposure. A practical checkpoint from here is whether Lilly’s upcoming regulatory submissions for Foundayo diabetes use and the EBGLYSS label update land on the timelines management has outlined, while the Nektar damages and any appeal outcomes clarify how material legal and settlement costs are to the broader business model.

    The one Eli Lilly question this article has not answered

    All the clinical news and courtroom updates still leave one big gap for investors, which is what Eli Lilly’s stream of cash flows suggests the whole business may be worth beside today’s share price. Find out exactly what Eli Lilly is worth today based on its cash flows.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.